These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 18997818)

  • 1. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
    Guigon CJ; Zhao L; Willingham MC; Cheng SY
    Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
    Furuya F; Lu C; Willingham MC; Cheng SY
    Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.
    Kim CS; Vasko VV; Kato Y; Kruhlak M; Saji M; Cheng SY; Ringel MD
    Endocrinology; 2005 Oct; 146(10):4456-63. PubMed ID: 16002527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
    Nozhat Z; Hedayati M
    Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.
    Guigon CJ; Fozzatti L; Lu C; Willingham MC; Cheng SY
    Carcinogenesis; 2010 Jul; 31(7):1284-91. PubMed ID: 20299527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
    Ying H; Willingham MC; Cheng SY
    Oncogene; 2008 Jan; 27(6):823-30. PubMed ID: 17653082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
    Furuya F; Hanover JA; Cheng SY
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1780-5. PubMed ID: 16446424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
    Zhu X; Kim DW; Zhao L; Willingham MC; Cheng SY
    Endocr Relat Cancer; 2016 Jul; 23(7):521-33. PubMed ID: 27267120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells.
    Minhajuddin M; Bijli KM; Fazal F; Sassano A; Nakayama KI; Hay N; Platanias LC; Rahman A
    J Biol Chem; 2009 Feb; 284(7):4052-61. PubMed ID: 19074768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
    Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
    Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.
    Cai J; Fang L; Huang Y; Li R; Yuan J; Yang Y; Zhu X; Chen B; Wu J; Li M
    Cancer Res; 2013 Sep; 73(17):5402-15. PubMed ID: 23856247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model.
    Kim WG; Park JW; Willingham MC; Cheng SY
    Endocrinology; 2013 Aug; 154(8):2936-47. PubMed ID: 23748362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
    Ramírez-Moya J; Wert-Lamas L; Santisteban P
    Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.
    Park JW; Han CR; Zhao L; Willingham MC; Cheng SY
    Endocr Relat Cancer; 2016 Jan; 23(1):53-63. PubMed ID: 26552408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
    Furuya F; Guigon CJ; Zhao L; Lu C; Hanover JA; Cheng SY
    Mol Cell Biol; 2007 Sep; 27(17):6116-26. PubMed ID: 17606624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PTEN/PI3K/Akt signaling pathway mediates HMGB1-induced cell proliferation by regulating the NF-κB/cyclin D1 pathway in mouse mesangial cells.
    Feng XJ; Liu SX; Wu C; Kang PP; Liu QJ; Hao J; Li HB; Li F; Zhang YJ; Fu XH; Zhang SB; Zuo LF
    Am J Physiol Cell Physiol; 2014 Jun; 306(12):C1119-28. PubMed ID: 24760979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer.
    Kim CS; Ying H; Willingham MC; Cheng SY
    Carcinogenesis; 2007 May; 28(5):932-9. PubMed ID: 17127711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.
    Furuya F; Lu C; Guigon CJ; Cheng SY
    Steroids; 2009 Jul; 74(7):628-34. PubMed ID: 19014961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
    Kato Y; Ying H; Willingham MC; Cheng SY
    Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.